Mark Hensley Joins Heron Therapeutics as Chief Operating Officer
Heron Therapeutics, Inc. (NASDAQ: HRTX), a leader in biotechnology, proudly announces the addition of Mark Hensley to its executive team as Chief Operating Officer. With over fifteen years of diverse experience in sales and operations within the pharmaceutical sector, Hensley is poised to significantly influence the company’s trajectory.
Experience and Expertise
Mark Hensley’s impressive background includes senior leadership roles at Veloxis Pharmaceuticals, where he served as Chief Executive Officer from 2021 to 2024. His expertise extends beyond this role; he was also the Chief Operating Officer and Chief Commercial Officer at Veloxis prior to that. Hensley’s career has been marked by a commitment to operational excellence and a robust understanding of company dynamics, perfectly aligning with Heron’s mission to enhance patient care.
Strategic Vision for Growth
In welcoming Hensley, Craig Collard, the CEO of Heron, expressed optimism about the potential impact of his operational leadership. “Mark brings extensive operational and leadership experience that positions him to play a pivotal role in our next phase of growth,” Collard stated. His insights are seen as essential for advancing Heron’s strategic priorities and executing growth initiatives.
Incentives and Stock Options
As part of Mr. Hensley's hiring package, he will receive a variety of inducement awards. This includes a non-statutory stock option to purchase 500,000 shares of Heron common stock. Additionally, he will be granted 500,000 restricted stock units and eligibility for a non-statutory stock option for up to 900,000 shares, subject to meeting specific performance-related stock price goals.
Inducement Awards Details
The inducement stock options are structured with a 10-year term and a four-year vesting schedule. Specifically, 25% of the shares will vest on the first anniversary of the grant date, with the remaining 75% vesting monthly over the following three years, contingent upon Hensley’s continued service. Similarly, the restricted stock units will vest at the same percentage on each anniversary of the grant date.
About Heron Therapeutics
Heron Therapeutics is dedicated to transforming the treatment landscape for patients through its innovative biotechnology solutions. The company focuses on therapeutic innovations that aim to elevate the standard of care in acute and oncology settings. By leveraging advanced scientific research and patented technologies, Heron has successfully developed and commercialized a range of products designed to improve medical care delivery.
Commitment to Excellence
The company’s mission reflects its deep commitment to patient welfare and advancing therapeutic outcomes. Heron Therapeutics remains at the forefront of addressing critical medical needs with its diverse product portfolio.
Frequently Asked Questions
Who is Mark Hensley?
Mark Hensley is the newly appointed Chief Operating Officer of Heron Therapeutics, bringing extensive experience from various leadership roles in the pharmaceutical industry.
What previous roles has Hensley held?
Prior to joining Heron, Mark Hensley served as Chief Executive Officer, Chief Operating Officer, and Chief Commercial Officer at Veloxis Pharmaceuticals.
What is the mission of Heron Therapeutics?
Heron Therapeutics aims to improve patient lives by developing and commercializing therapeutic innovations that enhance medical care.
What inducement awards will Mark Hensley receive?
Hensley will receive stock options, restricted stock units, and performance-based stock options as part of his employment compensation.
How does Heron Therapeutics benefit patients?
Heron focuses on advancing the standard of care through innovative treatments aimed at improving the overall healthcare experience for patients, particularly in acute and oncology care.
